



DL-453/0-2021

The development of clinical data on COVID-19 has been very rapid, resulting in a large amount of data being generated in a very short time. However, hard evidence still appears to be scarce. This article has been written to the best of our knowledge based on selected literature and opinions of clinical experts. It does not represent a summary of all available literature and therefore does not claim to be exhaustive. As COVID-19 is a very complex disease, you should always refer to the original literature mentioned in this article, other relevant literature and the circumstances of the individual case when deciding on the right ventilation strategy for your patients. It is also strongly advised to follow your national/local guidelines and standards.

The timing of intubation is a contentious issue: It is clearly critical, as delayed intubation is associated with a worse prognosis; at the same time, controversy exists regarding the role of early intubation vs. use of non-invasive respiratory support (NRS) to avoid intubation.⁴¹ However, one current review of twelve studies on close to 9,000 patients came to the conclusion that the timing of

intubation may actually have no effect on mortality and morbidity of critically ill COVID-19 patients ('early': intubation within 24h from ICU admission, 'late'= intubation any time after 24h of ICU admission); the conclusion was that these findings might well justify a "wait and see" approach, which in turn could lead to fewer intubations.⁴²



IMPORTANT:

All reviewed Guidelines recommend closely monitoring patients treated with HFNC or CPAP/NIV in order to not miss the right point for intubation. So possibly, it is once again not a matter of "early" vs. "late" as timing starting with admission to ICU, but rather a question of the right time for the individual patient.

However, only one of the reviewed guidelines provide specific information for the decision on when to perform endotracheal intubation.

Reviewed Guidelines:

- German S3 Guideline – Recommendations for the therapy of hospitalised patients with COVID-19, Version 4.1, February 2021 [referred to as **GS3**]³⁴
- Surviving Sepsis Guidelines on the Management of Adults with Coronavirus Disease 2019 (COVID-19) in the ICU: First Update; March 2021 [referred to as **SSC**]³⁵
- ERS Guideline for the Management of hospitalized adults with coronavirus disease 2019 (COVID-19): A European Respiratory Society living guideline, January 2021 [referred to as **ERS**]³⁶
- Australian guideline for clinical care of people with COVID-19, National COVID-19 Clinical Evidence Taskforce [referred to as **NCCET**]³⁷

GS3:

- Recommends considering intubation and mechanical ventilation of patients with severe hypoxemia ($P/F < 150$) and respiratory rate (RR) > 30 /min. In patients with $P/F < 100$ mmHg, intubation and mechanical ventilation is generally recommended.

Going through the existing literature, the monitoring of respiratory drive and effort along with other parameters seems to be in the foreground in order not to miss the right point in time for intubation.

What seems clear is that intubation should be patient-led, based not only on PaO_2/FiO_2 , but also on respiratory drive and specifically effort and risk of P-SILI. Patients who show signs of clinical deterioration or high respiratory distress that is not alleviated by non-invasive respiratory should promptly be intubated and treated with a lung-protective ventilation strategy.⁴¹

When to consider intubation?

- Worsening or unbearable dyspnea
- Lack of improvement in oxygenation
- Hemodynamic instability
- Persistent respiratory muscle fatigue
- Persistent tachypnea
- Neurologic deterioration

Parameters to monitor⁴³:

- **Every 1-3 hours**
 - PaO_2/FiO_2 ratio
 - Respiratory Rate
 - Signs of respiratory muscle fatigue
 - $PaCO_2$
 - Dyspnea
- **Continuous monitoring**
 - SaO_2
 - Blood Pressure
 - Heart Rate

Also, monitoring esophageal pressure (Pes) swings to identify excessive respiratory effort during NIV, as previously described above, may provide an indication of excessive respiratory effort.

Carteaux and colleagues studied the role of tidal volume in the failure of noninvasively ventilated patients with acute hypoxemic failure and conclude that “in patients with moderate-to-severe hypoxemia, the expired tidal volume above 9.5 mL/kg predicted body weight accurately predicts noninvasive ventilation failure.”⁴⁴

In an editorial, Pisano and colleagues state that most guidelines fail to provide concrete parameters for the decision for intubation and invasive ventilation, which we can confirm with regards to the guidelines reviewed for this article.⁴⁵ They discuss the reliability of common criteria for intubation, such as PaO₂/FiO₂ ratio, absolute PaO₂, SaO₂, and state that these might not be sufficiently precise as they are impacted by various variables. Therefore they suggest the following criteria:

1. Need for airway protection (alteration of consciousness)
2. Severe decompensated acidosis (e.g. pH <7.2-7.25)
3. Severe absolute hypoxemia (PaO₂ <50mmHg or SaO₂ <90%-92%) despite maximal non-invasive respiratory support
4. Signs and symptoms of significant respiratory distress or tissue hypoxia despite max. non-invasive respiratory support
5. Decision for ECMO in patients refractory (PaO₂/FiO₂ ratio <100mmHg, arterial partial pressure of carbon dioxide above 60mmHg, pH <7.2) to standard treatment.

Scores and scales to help making decision on intubation

Scores and Scales

A few scoring systems may provide support in the decision for ETI and invasive ventilation. To the best of our knowledge, there is no data available demonstrating superiority of one score over the other. Also, these scores for COVID-19 have not been fully validated, even though some data may be available.

Work of breathing scale. The above mentioned clinical scale for work of breathing described by Apigo et al. may be a simple clinical tool in this phase in addition to the available technical measurements also mentioned above.

ROX Index for patients receiving HFNC. The ROX-Index was introduced by Roca and colleagues in 2019 to provide support in the identification of patients with acute respiratory failure treated with HFNC running at low or high risk for intubation (HFNC failure).⁴⁶



ROX-Index:


$$\text{ROX index} = \frac{\text{SpO}_2/\text{FiO}_2}{\text{Respiratory Rate}}$$

A ROX Index >4.88 at 2, 6 or 12 hours after HFNC onset was consistently associated with a lower risk of mechanical ventilation, even after adjusting for potential confounding.

Thresholds described: 2h: <2.85; 6h: <3,47;
12h: <3,85.

ROX-Index for prediction of HFNC treatment failure


Ricard and colleagues suggested an algorithm for the systematic application of the ROX index in the decision making process for ETI⁴⁷.



The ROX index has been tested in COVID-19 patients by Zucman and colleagues. They conclude that “in this circumstance, the ROX index measured within the first 4 hours after NHF initiation could be an easy-to-use marker of early ventilatory response. Its most accurate cut-off was slightly higher than previously validated in AHRF, probably because of specific ventilatory adaptation observed in COVID-19-related AHRF.”⁴⁸

HACOR scale for noninvasively ventilated hypoxemic patients. Duan and colleagues introduced a scale assessing heart rate, acidosis, consciousness, oxygenation and respiratory rate in order to predict failures of noninvasively ventilated non-COVID hypoxemic patients.⁴⁹ They conclude: “The HACOR scale variables are easily obtained at the bedside. The scale appears to be an effective way of predicting NIV failure in hypoxemic patients”.

There is even an app for Android devices to calculate the **HACOR Score**.




Ref: HACOR Score App in Google Play Store

Algorithm from conventional oxygen therapy to

intubation. In their article “Knowledge translation tools to guide care of non-intubated patients with acute respiratory illness during the COVID-19 Pandemic”, Leasa and colleagues

propose an algorithm that may provide guidance from providing conventional oxygen therapy to the decision on ETI and invasive ventilation based on “best knowledge available”, and also incorporating indices such as the above mentioned ROX Index.⁴¹

Algorithm for respirator support in COVID-19 patients



In our article on ventilating patients with COVID-19-associated ARDS, we reviewed relevant literature and four current guidelines to provide a practical overview. For references and details, please visit our website: www.draeger.com/covid-ventilation



REFERENCES

1. Williams GW et al, *Anesthesiology* 2021;134:270; Pfortmueller CA et al, *Best Practice & Research Clinical Anaesthesiology* 2020; <https://doi.org/10.1016/j.bpa.2020.12.011>
2. Gattinoni L et al, COVID-19 Does Not Lead to a “Typical” Acute Respiratory Distress Syndrome; *Am J Respir Crit Care Med.* 2020 May 15;201(10):1299-1300. doi: 10.1164/rccm.202003-0817LE.
3. Grasselli G et al., Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study, *Lancet Respir Med.* 2020 Dec;8(12):1201-1208. doi: 10.1016/S2213-2600(20)30370-2. Epub 2020 Aug 27.
4. Chiumello D et al. Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study. *Intensive care medicine.* 2020;1-10. doi:10.1007/s00134-020-06281-2
5. Ferrando C. et al., Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS, *Intensive Care Med.* 2020 Dec;46(12):2200-2211. doi: 10.1007/s00134-020-06192-2. Epub 2020 Jul 29.
6. Cummings M. J. et al., Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, *Lancet.* 2020 Jun 6;395(10239):1763-1770. doi: 10.1016/S0140-6736(20)31189-2. Epub 2020 May 19.
7. Botta M. et al., Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PROVENT-COVID): a national, multicentre, observational cohort study, *Lancet Respir Med.* 2021 Feb;9(2):139-148. doi: 10.1016/S2213-2600(20)30459-8. Epub 2020 Oct 23.
8. Gattinoni L. et al., COVID-19 pneumonia: different respiratory treatments for different phenotypes?, *Intensive Care Med.* 2020 Jun;46(6):1099-1102. doi: 10.1007/s00134-020-06033-2. Epub 2020 Apr 14.
9. Marini JJ et al., Integrating the evidence: confronting the COVID-19 elephant, *Intensive Care Med.* 2020 Oct;46(10):1904-1907. doi: 10.1007/s00134-020-06195-z. Epub 2020 Jul 25
10. Gattinoni L et al., The Respiratory Drive: An Overlooked Tile of COVID-19 Pathophysiology, *Am J Respir Crit Care Med.* 2020 Oct 15;202(8):1079-1080. doi: 10.1164/rccm.202008-3142ED
11. Younes Zaid et al, Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19, Published online 2021 Jan 27. , doi: 10.1182/bloodadvances.2020003513
12. Chalmers JD et al, *Eur Resp J*, Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline, *Apr 15;57(4):2100048.* doi: 10.1183/13993003.00048-2021. Print 2021 Apr.
13. Tonelli R et al., Spontaneous Breathing and Evolving Phenotypes of Lung Damage in Patients with COVID-19: Review of Current Evidence and Forecast of a New Scenario, *J Clin Med.* 2021 Mar; 10(5): 975. Published online 2021 Mar 2. doi: 10.3390/jcm10050975
14. Osuchowski MF et al., The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity, *Lancet Respir Med.* 2021 May 6;S2213-2600(21)00218-6. doi: 10.1016/S2213-2600(21)00218-6. Online ahead of print
15. Esnault P et al, High Respiratory Drive and Excessive Respiratory Efforts Predict Relapse of Respiratory Failure in Critically Ill Patients with COVID-19, *Am J Respir Crit Care Med.* 2020 Oct 15; 202(8): 1173–1178. Published online 2020 Oct 15. doi: 10.1164/rccm.202005-1582LE
16. Takeshi Y et al, *CCM* 2013;41:536-545
17. Tonelli R et al., Early Inspiratory Effort Assessment by Esophageal Manometry Predicts Noninvasive Ventilation Outcome in De Novo Respiratory Failure A Pilot Study, *Am J Respir Crit Care Med.* 2020 Aug 15;202(4):558-567. doi: 10.1164/rccm.201912-2512OC
18. Gattinoni L et al., The Respiratory Drive: An Overlooked Tile of COVID-19 Pathophysiology, *Am J Respir Crit Care Med.* 2020 Oct 15;202(8):1079-1080. doi: 10.1164/rccm.202008-3142ED
19. Apigo et al. *Crit Care.* 2020 Jul 31;24(1):477
20. Carteaux G et al., Failure of Noninvasive Ventilation for De Novo Acute Hypoxemic Respiratory Failure: Role of Tidal Volume, *Crit Care Med.* 2016 Feb;44(2):282-90. doi: 10.1097/CCM.0000000000001379
21. Tobin MJ et al., *Am J Respir Crit Care Med.* 2020 Aug 1;202(3):356-360. doi: 10.1164/rccm.202006-2157CP.)
22. Vaporidi K et al., *Am J Respir Crit Care Med.* 2020 Jan 1;201(1):20-32. doi: 10.1164/rccm.201903-0596SO
23. Spinelli E et al., Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions, *Intensive Care Med.* 2020; 46(4): 606–618. Published online 2020 Feb 3. doi: 10.1007/s00134-020-05942-6
24. Bertoni M et al., A novel non-invasive method to detect excessively high respiratory effort and dynamic transpulmonary driving pressure during mechanical ventilation, *Crit Care.* 2019 Nov 6;23(1):346. doi: 10.1186/s13054-019-2617-0
25. Tomasino S et al, *Semin Cardiothorac Vasc Anesth* 2020;24:287-292
26. Morais CCA et al. Bedside electrical impedance tomography unveils respiratory “chimera” in COVID-19. *Am J Respir Crit Care Med.* 2021;203(1):120-1
27. Kotani T et al., Roles of Electrical Impedance Tomography in Determining a Lung Protective Strategy for Acute Respiratory Distress Syndrome in the Era of Coronavirus Disease 2019, *JAMA J.* 2021;4(2):81-85. DOI: 10.31662/jmaj.2021-0014
28. Gattinoni L. et al., COVID-19 and ARDS: the baby lung size matters, *Intensive Care Med.* 2021; 47(1): 133–134. Published online 2020 Dec 4. doi: 10.1007/s00134-020-06324-8
29. Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators et al., ‘Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial’, *JAMA*, 27 September 2017, <https://doi.org/10.1001/jama.2017.14171>
30. Zhao Z et al., ‘Positive End-Expiratory Pressure Titration with Electrical Impedance Tomography and Pressure–Volume Curve in Severe Acute Respiratory Distress Syndrome’, *Annals of Intensive Care* 9, no. 1 (December 2019): 7, <https://doi.org/10.1186/s13613-019-0484-0>

31. Zarantonello F et al., 'Prone Position and Lung Ventilation/Perfusion Matching in Acute Respiratory Failure Due to COVID-19', *American Journal of Respiratory and Critical Care Medicine*, 21 May 2020, rccm.202003-07751M, <https://doi.org/10.1164/rccm.202003-07751M>
32. Guérin C et al., 'A Prospective International Observational Prevalence Study on Prone Positioning of ARDS Patients: The APRONET (ARDS Prone Position Network) Study', *Intensive Care Medicine* 44, no. 1 (2018): 22–37, <https://doi.org/10.1007/s00134-017-4996-5>.
33. Wiggermann N et al., 'Prone Positioning of Patients With COVID-19: A Review of Equipment and Methods', *Human Factors*, 16 August 2020, 0018720820950532, <https://doi.org/10.1177/0018720820950532>
34. German S3 Guideline – Recommendations for the therapy of hospitalised patients with COVID-19, Version 4.1, February 2021
35. Surviving Sepsis Guidelines on the Management of Adults with Coronavirus Disease 2019 (COVID-19) in the ICU: First Update; March 2021; doi: 10.1097/CCM.0000000000004899.
36. ERS Guideline for the Management of hospitalized adults with coronavirus disease 2019 (COVID-19): A European Respiratory Society living guideline, January 2021, DOI: 10.1183/13993003.00048-2021
37. Australian guideline for clinical care of people with COVID-19, National COVID-19 Clinical Evidence Taskforce (Link)
38. Grieco DL et al., Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial, *JAMA*. 2021 May 4;325(17):1731-1743. doi: 10.1001/jama.2021.4682
39. Perkins GD et al., RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial, *Trials*. 2020 Jul 29;21(1):687. doi: 10.1186/s13063-020-04617-3
40. Patel BK et al., Effect of Noninvasive Ventilation Delivered by Helmet vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial, *JAMA*. 2016 Jun 14;315(22):2435-41. doi: 10.1001/jama.2016.6338
41. Leasa D et al., Knowledge translation tools to guide care of non-intubated patients with acute respiratory illness during the COVID-19 Pandemic, *Crit Care*. 2021 Jan 8;25(1):22. doi: 10.1186/s13054-020-03415-2
42. Papoutsis E et al, *Crit Care* 2021;25:121
43. Raoof S et al., High-Flow, Noninvasive Ventilation and Awake (nonintubated) prone in Patients with Coronavirus Disease 2019 with Respiratory Failure, *Chest*. 2020 Nov;158(5):1992-2002. doi: 10.1016/j.chest.2020.07.013. Epub 2020 Jul 15.]
44. Carteaux G et al., Failure of Noninvasive Ventilation for De Novo Acute Hypoxemic Respiratory Failure: Role of Tidal Volume, *Crit Care Med*. 2016 Feb;44(2):282-90. doi: 10.1097/CCM.0000000000001379
45. Pisano A et al., Indications for Tracheal Intubation in Patients With Coronavirus Disease 2019 (COVID-19), *J Cardiothorac Vasc Anesth*. 2021 May; 35(5): 1276–1280
46. Roca O et al., An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy, *Am J Respir Crit Care Med*. 2019 Jun 1;199(11):1368-1376. doi: 10.1164/rccm.201803-0589OC
47. Ricard JD et al., Use of nasal high flow oxygen during acute respiratory failure, *Intensive Care Med*. 2020 Sep 8 : 1–10. doi: 10.1007/s00134-020-06228-7
48. Zucman N et al., Prediction of outcome of nasal high flow use during COVID-19-related acute hypoxemic respiratory failure, *Intensive Care Med*. 2020 Jul 15 : 1–3. doi: 10.1007/s00134-020-06177-1
49. Duan J et al., Assessment of heart rate, acidosis, consciousness, oxygenation, and respiratory rate to predict noninvasive ventilation failure in hypoxemic patients, *Intensive Care Med*. 2017 Feb;43(2):192-199. doi: 10.1007/s00134-016-4601-3. Epub 2016 Nov 3.]
50. Brault C et al, *AJRCCM* 2020, doi 10.1164/rccm.202005-2025LE
51. Telias I et al., 'Airway Occlusion Pressure As an Estimate of Respiratory Drive and Inspiratory Effort during Assisted Ventilation', *American Journal of Respiratory and Critical Care Medicine* 201, no. 9 (1 May 2020): 1086–98, <https://doi.org/10.1164/rccm.201907-1425OC>.
52. Positionspapier zur praktischen Umsetzung der apparativen Differenzialtherapie der akuten respiratorischen Insuffizienz bei COVID-19: Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. (DGP), https://www.researchgate.net/publication/340865640_Positionspapier_zur_praktischen_Umsetzung_der_apparativen_Differenzialtherapie_der_akuten_respiratorischen_Insuffizienz_bei_COVID-19_Deutsche_Gesellschaft_fur_Pneumologie_und_Beatmungsmedizin_eV_DGP
53. Rose L et al., 'Automated versus Non-Automated Weaning for Reducing the Duration of Mechanical Ventilation for Critically Ill Adults and Children', *Cochrane Database Syst Rev* 6 (2014).
54. Lellouche F et al., 'A Multicenter Randomized Trial of Computer-Driven Protocolized Weaning from Mechanical Ventilation', *American Journal of Respiratory and Critical Care Medicine* 174, no. 8 (15 October 2006): 894–900, <https://doi.org/10.1164/rccm.200511-1780OC>.
55. Taenaka H. et al., Individualized ventilatory management in patients with COVID-19-associated acute respiratory distress syndrome, *Respir Med Case Rep*. 2021; 33: 101433. Published online 2021 May 31. doi: 10.1016/j.rmcr.2021.101433
56. Zhao Z. et al., The use of electrical impedance tomography for individualized ventilation strategy in COVID-19: a case report, *BMC Pulm Med*. 2021; 21: 38. Published online 2021 Jan 22. doi: 10.1186/s12890-021-01441-y

IMPRINT

GERMANY
 Drägerwerk AG & Co. KGaA
 Moislinger Allee 53–55
 23542 Lübeck

www.draeger.com